![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
2-Year Outcomes of Dolutegravir (DTG) and Lamivudine (3TC) in Art-Naive and Pre-treated People Living With HIV in Germany: Real-world Data From the German URBAN Cohort
|
|
|
Glasgow 2022 Oct 23-26
Daniel Beer,1 Jenny Scherzer,2 Sebastian Noe,3 Stefan Scholten,4 Christoph Wyen,5 Nils Postel,6 Olaf Degen,7 Michael Sabranski,8 Bernd Westermayer,9 Kathrin M. Dymek2
1PZB Aachen - Praxis Dr. H. Knechten, Aachen, Germany; 2ViiV Healthcare, Munich, Germany; 3MVZ München am Goetheplatz, Munich, Germany; 4Praxis Hohenstaufenring, Cologne, Germany; 5Praxis Ebertplatz, Cologne,
Germany; 6prinzmed, Munich, Germany; 7Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; 8Infektionsmedizinisches Zentrum Hamburg (ICH), Hamburg, Germany; 9GSK, Munich, Germany
![1028221](../images/102822/102822-9/1028221.gif)
![1028222](../images/102822/102822-9/1028222.gif)
![1028223](../images/102822/102822-9/1028223.gif)
![1028224](../images/102822/102822-9/1028224.gif)
![1028225](../images/102822/102822-9/1028225.gif)
![Acknowledge](../images/102822/102822-16/Acknowledge.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|